Cargando…

FRI683 Every Dose Counts: Response To Half The Recommended Dose Of Romosozumab

Disclosure: B.P. Ramchandani: None. F.S. Mirza: None. Introduction: Romosozumab (RSB) is a monoclonal antibody that inhibits sclerostin, increases bone formation and decreases bone resorption. It was approved by FDA in 2019 at a dose of 210 mg monthly for 1 year, followed by an anti-resorptive medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramchandani, Bhanvi Prakash, Mirza, Faryal Sardar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554798/
http://dx.doi.org/10.1210/jendso/bvad114.451